24 results on '"Forman, S."'
Search Results
2. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL).
3. Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk locally advanced/inflammatory and metastatic breast cancer.
4. Functional impairment (FI) after hematopoietic cell transplantation (HCT) and impact on quality of life (QOL).
5. Is low-dose cyclophosphamide (Cy) plus G-CSF (G) mobilization as effective as plerixafor plus G in multiple myeloma (MM) patients (pts) who are candidates for tandem autologous transplants (autoT)?
6. Challenges for retrospective cohort studies: A profile of patients who refuse participation or are lost to follow-up
7. Impact of hematopoietic cell transplantation (HCT) for hematologic malignancies on self-reported fatigue and vigor
8. Health care utilization by adult Hispanic long term survivors of hematopoietic cell transplantation (HCT): report from the bone marrow transplant survivor study
9. A new tandem autologous peripheral blood progenitor cell transplant (AT) approach incorporating total marrow irradiation (TMI) for patients (pts) with multiple myeloma (MM)
10. Late clinical heart failure (CHF) following hematopoietic cell transplantation (HCT)
11. Phase 2 study of suberoylanilide hydroxamic acid (SAHA) in relapsed or refractory indolent non-Hodgkin lymphoma: A California Cancer Consortium study
12. Phase I trial of escalating doses of total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan and PBPC as part of tandem high-dose therapy (THDT) for patients with multiple myeloma (MM)
13. Impact of rituximab on outcome of autologous transplantation for mantle cell lymphoma
14. The outcome of ZBEAM, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non-Hodgkin’s lymphoma (NHL)
15. Late mortality in two-year survivors of hematopoietic cell transplantation (HCT) performed in children and adolescents: Report from the BMT-Survivor Study
16. High-dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high-dose etoposide (VP-16) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor-risk or relapsed B-cell non-Hodgkin's lymphoma (NHL): Update of a phase I/II trial
17. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
18. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.
19. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
20. Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.
21. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease.
22. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia.
23. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.
24. Bone marrow transplantation for hematologic malignancies in patients aged 30 years or older.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.